InflaRx N.V.

General information
InflaRx N.V.
Winzerlaer Str. 2
07745 Jena, Thuringia
Germany

Contact person: Niels C. Riedemann, Chief Executive Officer and Founder
Company main phone: +49 (3641) 508180
Website:  https://www.inflarx.de
Year founded:2007
Source of foundation:Independent foundation
Name of foundation source:Founded by Dr. Niels C. Riedemann and Dr. Renfeng Guo
No. of employees: Worldwide:  65
Corporate description / mission:
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies. InflaRx is also developing izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2017
Remarks on ownership / listings
InflaRx has offices in Jena and Munich, Germany and a research facility in Ann Arbor, Michigan.
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Anti-infectives
  • Antibodies
  • Small molecules
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the nervous system / neurology
  • Genitourinary system / Urology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • In-licensing
  • Manufacturer
  • R&D
  • Supplier / Distributor
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
  • Small biotech
Distribution:
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:1
Phase I:3
Phase II:3
Phase III:1
On the market:2
Description of products:
Vilobelimab
Izicopan
Technology used:
Anti C5a/C5aR Technology
Financing details
Fiscal year (end of) 2025
Revenues:USD 0.03M
R&D expenses:USD 28.95M
Cash:USD 18.76M
No. of shares:72'292'859
Market cap. / valuation:USD 186.52M
© 2026 Biotechgate by Venture Valuation
X